This review discusses where we stand today on anemia management in cancer patients and examines the balance between studies that show higher erythropoiesis-stimulating agent–associated mortality and those that do not show erythropoiesis-stimulating agent–associated mortality.
Read the original article at The Oncologist.
Update on Erythropoiesis-Stimulating Agents and Clinical Trials in Oncology
Most recent items in "Клинични проучвания":
9th Oct Клинични проучвания: A phase 2 study of vorinostat in acute myeloid leukemia
The therapeutic potential of histone deacetylase inhibitors, such as vorinostat, in acute myeloid leukemia has raised considerable interest. Here the authors describe outcomes with two different schedules of this drug in patients with "poor-prognosis" or relapsed acute myeloid le...
Анатомия и физиология
|
|
Биохимия
|
|
Биоинформатика
|
|
Кардиология
|
|
Молекулярна и клетъчна биология
|
|
Клинични проучвания
|
| A phase 2 study of vorinostat in acute myeloid leukemia Update on Erythropoiesis-Stimulating Agents and Clinical Trials in Oncology |
|
Биология на развитието
|
|
Генетика
|
|
Хематология
|
|
Имунология
|
|
Микробиология и вирусология
|
|
Нанотехнологии
|
|
Неврология
|
|
Онкология
|
|
Патология
|
|
Фармакология
|
|
Растителни биотехнологии
|
|
Протеомика
|
|
Сигнална трансдукция
|
|
Стволови клетки
|
|
Тъканно инженерство
|
|
|
2008 - 2010 LifeSciences.BG
| Some rights reserved